Patents by Inventor Charles K. Thodeti

Charles K. Thodeti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for treating ischemic heart disease by targeting TRPV4
    Patent number: 11058707
    Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.
    Type: Grant
    Filed: November 2, 2018
    Date of Patent: July 13, 2021
    Assignee: Northeast Ohio Medical University
    Inventor: Charles K. Thodeti
  • Methods for Treating Ischemic Heart Disease by Targeting TRPV4
    Publication number: 20200000837
    Abstract: Methods useful for treating ischemic heart disease, reducing cardiac fibrosis, improving cardiac function, or increasing coronary angiogenesis are described.
    Type: Application
    Filed: November 2, 2018
    Publication date: January 2, 2020
    Applicant: Northeast Ohio Medical University
    Inventor: Charles K. Thodeti
  • Improving efficacy of cancer therapy
    Patent number: 9078856
    Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.
    Type: Grant
    Filed: June 22, 2011
    Date of Patent: July 14, 2015
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Charles K. Thodeti, Donald E. Ingber
  • METHODS OF MODULATING ANGIOGENESIS VIA TRPV4
    Publication number: 20150132321
    Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.
    Type: Application
    Filed: November 7, 2014
    Publication date: May 14, 2015
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Charles K. Thodeti
  • EFFICACY OF CANCER THERAPY
    Publication number: 20130150432
    Abstract: Embodiments of the invention provide a method of improving the efficacy of an anti-cancer therapy and a method of treatment of cancer by normalizing angiogenesis in cancer. By enhancing the cell signaling pathway via a TRPV4 receptor in tumor endothelial cells, either by a TRPV4 agonist or by increasing the expression of TRPV4 in the tumor endothelial cells, the tumor endothelial cells behave normally and form normal angiogenic network for better anti-cancer therapy to the tumors.
    Type: Application
    Filed: June 22, 2011
    Publication date: June 13, 2013
    Applicants: NORTHEAST OHIO MEDICAL UNIVERSITY, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Charles K Thodeti, Donald E. Ingber
  • Methods of modulating angiogenesis via TRPV4
    Patent number: 8394779
    Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis. Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: March 12, 2013
    Assignee: Children's Medical Center Corporation
    Inventors: Donald E. Ingber, Charles K. Thodeti
  • METHODS OF MODULATING ANGIOGENESIS VIA TRPV4
    Publication number: 20110150894
    Abstract: The present invention relates to methods of inhibiting capillary endothelial (CE) cell migration, the formation of CE networks and angiogenesis, and uses thereof for the purpose of treating angiogenesis-related diseases and disorders, particularly when the diseases or disorders are directly related aberrant angiogenesis Inhibition is achieved by inhibiting TRPV4 activity, such as the levels of TRPV4 expression, calcium influx through TRPV4, and/or the intracellular signaling from TRPV4 via ?1 integrin activation.
    Type: Application
    Filed: June 4, 2009
    Publication date: June 23, 2011
    Applicant: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Charles K. Thodeti